Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Checkpoint inhibitor monotherapy in potentially studyeligible or non-study-eligible NSCLC patients in the German CRISP Registry real-world cohort (AIO-TRK-0315).

F Griesinger; M Sebastian; W Brückl; H-D Hummel; B Jaeschke; J Kern; C Wesseler; M Jänicke; A Fleitz; S Zacharias; A Hipper; A Groth; W Weichert; S Dörfel; V Petersen; J Schröder; J Wilke; W E E Eberhardt; M Thomas, 2022.

Oncol Res Treat 2022;45(suppl 1):151

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CRISP
2022
RAS mutant metastatic colorectal cancer – Real-world data from more than 1000 patients from the Clinical Tumor Registry Colorectal Cancer (TKK).

Dörfel S, Bernhardt C, Eggers E, Fruehauf S, Maintz C, Behringer J, u. a.

Oncol Res Treat. 2022;45(suppl 1)(245):64.

Download

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
TKK
2022
Implementation of new tests and treatments for patients with advanced triple negative breast cancer in routine care – data from the registry platform OPAL

Zahn MO, Welt A, Thill M, Stickeler E, Zaiss M, Nusch A, u. a.

Oncol Res Treat. 2022;45(suppl 1)(246):23.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
OPAL
2022
First results from the prospective national intersectoral cohort study JADE to assess characteristics, treatment and outcome of patients with hepatocellular or cholangiocellular carcinoma in Germany.

Thimme R., Schröder J., Uhlig J., Freiberg-Richter J., Zingerle M.; Schlenska-Lange A., Hering-Schubert C., Potthoff K., Bengsch F., Hillebrand L.E., Siebenbach H.U., Jänicke M., Hofmann W.P., Pereira P., Galle P.R., Berg T., JADE Registry Group, 2022.

Oncol Res Treat 2022; 45(suppl 1) (P211), 80.

Link

Indikation: Leberkrebs, Liver Cancer / Veranstaltung: DKK / Journal: Oncology Research and Treatment
JADE
2022
Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany – AIO-TRK-0315.

Gröschel A, Passlick B, Stuschke M, Christopoulos P, Reck M, Grah C, et al.

Oncol Res Treat. 2022;45(suppl 1)(Abstract 135):148.

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CRISP
2022
Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Real-World Evidence zu NSCLC Patienten behandelt mit Radiochemotherapie.

Eberhardt WEE, Passlick B, Stuschke M, Groeschel A, Christopoulos P, Reck M, et al., 2022.

Oncol Res Treat 2021;44:1–335

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2022
Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315.

Eberhardt WEE, Passlick B, Stuschke M, Groeschel A, Christopoulos P, Reck M, et al. 2022.

Annals of Oncology. 2022 Sep;33(Supplement 7):S988.

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
CRISP
2022
CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany – AIO-TRK-0315

Stuschke M, Eberhardt WEE, Passlick B, Groeschel A, Christopoulos P, Reck M, et al. 2022.

Abstract Book WCLC 2022, p. 579
EP05.01-030

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: IASLC (WCLC) / Journal: -
CRISP
2022
Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-World Evidence of NSCLC Stage I, II and III in Germany – AIO-TRK-0315.

Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, et al. 2022.

Zentralbl Chir. 2022;147(S 01):S47–8.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGT / Journal: Zentralblatt für Chirurgie

CRISP
2022
Patientencharakteristika zur Baseline der BERING CRC Studie: Real-World Daten zum BRAF V600E-mutierten metastasierten Kolorektalkarzinom.

Bonnin-Gruber Y., Schröder J., Forstbauer H., Kisro J., Welslau M., Müller-Huesmann H., Bürkle D., Krammer-Steiner B., von der Heyde E., Reichenbach F., Arnold D., Fritsch R., Gerger A., Hegewisch-Becker S., Vogel A., Winder T., Koeberle D., Prager G., Stintzing S., 2022.

Oncol Res Treat 2022;45(suppl 2):315

Download

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
BeringCRC
2022